Jeffrey T. Schouten, M.D. Img

Jeffrey T. Schouten, M.D.

Index of STEP Conference Summaries by Topic
The Body's Conference Summaries

Jeffrey Schouten, M.D. Dan Dawson Richard March In an effort to provide comprehensive coverage of 7th annual Retrovirus Conference and Opportunistic Infections, one of the most important annual meeting concerning HIV/AIDS, The Body is please to provide daily coverage from Seattle Treatment Education Project (STEP) one of the earliest AIDS service organizations in America. Same day coverage will be provided by four of STEP's treatment specialists. Jeff Schouten, M.D. Jeff is a former surgeon who has been living with HIV for over 10 years. Jeff has been the chair of STEP's scientific review committee for several years and is currently chair of STEP's Scientific Advisory Board. He also is co-editor of the STEP Perspective and is also a frequent contributor. Dan Dawson is the co-executive director of the Seattle Treatment Education Project (STEP) and the editor of the STEP Perspective, the HIV/AIDS treatment journal. He has been working in the HIV/AIDS field for almost seven years and has been in the heatlh care field for over 15 years. Brian Coppedge was the treatment information specialist for STEP from 1996 until 1999. Since 1999 Brian has been the co-executive director responsible for programs at STEP. This is the fourth Retrovirus Conference he has attended. Richard March has been a treatment specialist with STEP since November,1999. He has worked as a volunteer for various AIDS service organizations for the last seven years.

Index of STEP Conference Summaries

Sunday, January 30, 2000

  • Opening Session
    Coverage by Jeffrey Schouten, M.D.

    • Bernard Fields Memorial Lecture: Our Retroviral Heritage
    • Keynote Lecture: The State of HIV Vaccine Research
  • Session 7 -- Pathogenesis and Mechanisms of Metabolic Abnormalities
    Session 8 -- Metabolic Complications: Effects of Switching Antiretroviral Therapy and Other Interventions
    Coverage by Richard March

    • Poster 44: Why Some Fat Depots Waste but Others Expand in Patients Using Protease Inhibitors: Hypothesis and Supporting Data
    • Poster 45: A Prospective Open Label Pilot Trial of a Maintenance Nevirapine (NVP)-Containing Regimen in Patients with Undetectable Viral Loads (VL) on Protease Inhibitor (PI) Regimens for at Least 6 Months
    • Poster 52: Reversibility of Peripheral Fat Wasting (Lipoatrophy) on Stopping Stavudine Therapy
  • Session 12 -- Adherence to Chemotherapeutic Regimens
    Coverage by Jeffrey Schouten, M.D.

    • Poster 69: Adherence and Viral Load in HIV-Infected Drug Users: Comparison of Self-Report and Medication Event Monitors (MEMS)
    • Poster 71: Impact of Directly Observed Therapy on Outcomes in HIV Clinical Trials
  • Session 13 -- Pharmacology: Drug Interactions
    Coverage by Jeffrey Schouten, M.D.

    • Poster 76: Effect of Simultaneous or Staggered Dosing of Saquinavir (SQV), Ritonavir (RTV), and Nelfinavir (NFV) on Pharmacokinetic (PK) Interactions
    • Poster 77: Pharmacokinetic (PK) Drug-Interaction between Amprenavir (APV) and Ritonavir (RTV) in HIV-Seronegative Subjects after Multiple, Oral Dosing
    • Poster 78: The Addition of a Second Protease Inhibitor Eliminates Amprenavir-Efavirenz Drug Interactions and Increases Plasma Amprenavir Concentrations
  • Session 22 -- Symposium: New Drug Targets: Integrase Inhibitors
    Coverage by Brian Coppedge

    • Symposium Summary
  • Session 24 -- Symposium: Emerging Issues in Hepatitis C Infection
    Coverage by Jeffrey Schouten, M.D.

    • S8: Epidemiology and Natural History of Hepatitis C
    • S9: Molecular Virology of Hepatitis C: An Overview
    • S10:The Immunopathogenesis of Hepatitis C Virus
    • S11:The Treatment of Chronic HCV Infection in HIV-Infected Persons

Monday, January 31, 2000

  • Session 36 -- Antiviral Therapy: Resistance and Reservoirs
    Coverage by Brian Coppedge

    • Slide 233: Measuring the Replicative Fitness of Recombinant HIV-1 Vectors Expressing Protease and Reverse Transcriptase Derived from Patient Viruses
    • Slide 234: Reduced Susceptibility to NRTI Is Associated with NNRTI Hypersensitivity in Virus from HIV-1-Infected Patients
    • Slide 237: Phenotypic Resistance Testing Significantly Improves Response to Therapy (Tx): A Randomized Trial (VIRA 3001)
  • Session 37 -- Primary and Secondary Prevention of Opportunistic Infections in the Era of HAART
    Coverage by Richard March

    • Poster 241: Low Rates of All Opportunistic Infections among Patients with Advanced HIV Disease Responding to Antiretroviral Therapy -- the CPCRA 048 Cohort

Tuesday, February 1, 2000

  • Session 61 -- Antiviral Therapy: Clinical Trials
    Coverage by Richard March and Jeffrey Schouten, M.D.

    • Slide 451: Patterns of Plasma HIV RNA Responses in Antiretroviral Treatment Success and Failure
    • Slide 452: CCR5 D32 Deletion and Response to HAART in HIV-1-Infected Patients
    • Slide 453: Improvement in CD4 T-Cell Counts Despite Virologic Treatment Failure: Role of Thymic Output
    • Slide 454: Association of Viral Load, CD4 Cell Count, and Treatment with Clinical Progression in HIV Patients with Very Low CD4 Cell Counts: The EuroSIDA Cohort
    • Slide 455: Pharmacodynamics (PD) of Indinavir (IDV) in Protease-Naïve HIV-Infected Patients Receiving ZDV and 3TC
    • Slide 457: Protease Inhibitor Class-Sparing Maintenance Therapy with Abacavir (ABC) + Lamivudine (3TC) + Zidovudine (ZDV) in Patients with Long-Term Suppression of HIV-1 RNA
    • Slide 458: SITT: A Prospective Trial of Strategic Treatment Interruptions
  • Session 68 -- Antiretroviral Therapy in Treatment-Naïve Patients
    Coverage by Jeffrey Schouten, M.D.

    • Poster 510: Preliminary Results of a Randomized Multicenter Study Comparing Combivir (ZDV/3TC) plus Nelfinavir or Nevirapine in HIV-Infected Naïve Patients (COMBINE Study)
    • Poster 515: ABT-378/ritonavir (ABT-378/r) in Antiretroviral-Naïve HIV-Positive Patients: 72 Weeks
    • Poster 518: A Pilot Study of FTC + ddI + Efavirenz in Treatment-Naïve HIV-Infected Adult: A Potent and Convenient Once-a-Day HAART (ANRS 091 Trial)
  • Session 69 -- Antiretroviral Chemotherapy: Treatment-Experienced Patients
    Coverage by Jeffrey Schouten, M.D.

    • Poster 531: ACTC 364- Nelfinavir (NFV) and/or Efavirenz (EFV) in Combination with New NRTIs in Nucleoside-Experienced Subjects (Subj): Week-48 Ultrasensitive (US) HIV RNA Results
    • Poster 532: ABT-378/Ritonavir (ABT-378/r) Suppresses HIV RNA to <400 Copies/ml in 84% of Protease Inhibitor-Experienced Patients at 48 weeks
    • Poster 534: Ritonavir Intensification in Indinavir Recipients with Detectable HIV RNA Levels

Wednesday February 2, 2000

  • Session 78 -- State of the Art Lecture: Critical Issues in Antiretroviral Therapy
    Coverage by Richard March

  • Session 83 -- Antiviral Therapy: New Drugs
    Coverage by Jeffrey Schouten, M.D.

    • Poster 668: Anti-HIV Activity and Tolerability of DAPD, a Novel Dioxolane Guanosine RT Inhibitor: Initial Results of a Phase I/II 14-Day Monotherapy Clinical Trial
    • Poster 672: Safety and Antiviral Efficacy of a Novel Once-Daily HIV-1 Protease Inhibitor BMS-232632: Preliminary Results from a Phase II Clinical Trial
    • Poster 673: The Safety, Efficacy and Viral Dynamics Analysis of Tipranavir, a New-Generation Protease Inhibitor, in a Phase II Study in Antiretroviral-Naive HIV-1-Infected Patients
  • Late Breaker Session 2 -- Documentation of HIV-1 Superinfection and Acceleration of Disease Progression
    Coverage by Richard March

  • Late Breaker Session 5 -- It Is Safe to Discontinue Secondary Prophylaxis for PCP in HIV-Infected Patients Treated with HAART
    Coverage by Richard March

  • Late Breaker Session 6 -- Pharmacokinetic Interactions between Protease Inhibitors and Selected HMG-CoA Reductase Inhibitors
    Coverage by Jeffrey Schouten, M.D.

  • Late Breaker Session 7 -- A Randomized, Placebo-Controlled Trial of Saquinavir, Indinavir or Nelfinavir in Combination with Amprenavir, Abacavir, Efavirenz & Adefovir in Patients with PI Failure
    Coverage by Jeffrey Schouten, M.D.

  • Late Breaker Session 10 -- Virologic and Immunologic Evaluation of Structured Treatment Interruptions in Patients Experiencing Long-term Virologic Failure
    Coverage by Jeffrey Schouten, M.D.

  • Late Breaker Session 11 -- Structured Cyclic Antiretroviral Therapy Interruption in Chronic Infection May Induce Immune Responses Against HIV-1 Antigens Associated with Spontaneous Drop in Viral Load
    Coverage by Jeffrey Schouten, M.D.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Latest by Jeffrey T. Schouten, M.D.

Promo Image

Fuzeon (T-20), the First HIV Entry Inhibitor, Is Now FDA-Approved

The FDA approved licensing of Fuzeon on March 20, 2003. There remain, however, two major unanswered questions about this drug. The first is when Fuzeon should be used. The second is whether there are adequate supplies to meet the anticipated need for...

By Jeffrey T. Schouten, M.D. for Seattle Treatment Education Project
Promo Image

Therapeutic Drug Monitoring: The Next Best Thing in HIV Treatment?

Therapeutic drug monitoring (TDM) uses blood levels of a drug to adjust its dose to achieve the maximal benefit and/or to achieve the minimal toxicity. This approach to customizing drug dosing has great appeal for the treatment of HIV. The promise of...

By Jeffrey T. Schouten, M.D. and Rolf Christensen, D.D.S. for Seattle Treatment Education Project
Promo Image

Ask Dr. Jeff: Is There a "Morning-After" Pill for HIV Exposure?

Question: Is there a "morning-after" pill for HIV exposure? What can be done if someone is exposed to HIV infection?

Answer: This question is arising more often in clinical practice. First, it is important to differentiate exposure in an occupatio...

By Jeffrey T. Schouten, M.D. for Seattle Treatment Education Project
Promo Image

Second-Generation Drugs Fight Resistant Virus

There are now 13 FDA-approved drugs to treat HIV and 2 more drugs -- adefovir and amprenavir -- are in expanded access. Amprenavir is a protease inhibitor (PI) that may have some activity against HIV strains that are resistant to the four currently a...

By Jeffrey T. Schouten, M.D., Dan Dawson and Brian Coppedge, HIV Treatment Specialist, for Seattle Treatment Education Project